sarscoronaviru
sarscov
newli
emerg
highli
pathogen
agent
caus
human
infect
nearli
death
novemb
septemb
direct
persontoperson
transmiss
via
respiratori
droplet
account
case
mode
rule
sarscov
viraemia
seem
reach
high
titr
howev
exclud
viru
transmiss
may
occur
via
blood
transfus
applic
therapeut
plasma
product
eg
freshfrozen
plasma
singl
compon
deriv
thereof
manufactur
process
plasma
deriv
requir
compris
dedic
viru
inactivationremov
step
treatment
mixtur
solvent
deterg
sd
success
appli
inactiv
member
transfusionrelev
virus
without
affect
therapeut
properti
product
sd
treatment
irrevers
disrupt
lipid
envelop
virus
hiv
hbv
hcv
hgv
cmv
studi
evalu
manufactur
process
immunoglobulin
prepar
octagam
manufactur
octapharma
pharmazeutika
produktionsgesmbh
vienna
austria
capac
inactiv
sarscov
result
demonstr
sarscov
complet
inactiv
limit
detect
found
occur
within
min
sd
treatment
sever
acut
respiratori
syndrom
sar
novel
infecti
diseas
first
occur
china
novemb
known
public
februari
sar
caus
newli
emerg
viru
belong
coronavirida
famili
provision
term
sarscoronaviru
sarscov
avail
sequenc
data
indic
sarscov
clearli
differ
previous
known
coronavirus
new
fourth
genet
lineag
propos
sarscov
although
humantohuman
transmiss
sarscov
less
effici
airborn
virus
influenza
virus
recent
sar
epidem
characteris
sever
explos
outbreak
infect
result
direct
transmiss
via
respiratori
droplet
close
person
contact
adequ
protect
measur
shown
effect
howev
number
instanc
transmiss
occur
mode
yet
well
defin
central
china
around
probabl
sar
patient
appar
histori
close
person
contact
anoth
victim
least
portion
case
may
arisen
mode
transmiss
differ
respiratori
droplet
besid
viru
shed
stool
sampl
sarscov
viraemia
occur
seem
reach
high
titr
copiesml
sarscovepidem
concern
rais
possibl
sarscov
transmiss
transfus
blood
compon
therapeut
plasma
product
manufactur
process
plasma
deriv
requir
compris
dedic
viru
inactivationremov
step
envelop
virus
treatment
mixtur
solvent
deterg
sd
use
mani
manufactur
worldwid
success
appli
clot
factor
immunoglobulin
prepar
sd
treatment
caus
envelop
virus
irrevers
destroy
includ
human
immunodefici
viru
type
c
hepat
b
viru
hbv
hepat
c
viru
hcv
hepat
g
viru
hgv
human
cytomegaloviru
cmv
basi
exist
valid
data
envelop
virus
anticip
inactiv
remov
step
incorpor
manufactur
process
plasmaderiv
medicin
product
also
effect
sarscov
confirm
assumpt
verif
studi
sarscov
perform
sd
treatment
condit
use
manufactur
immunoglobulin
concentr
intend
intraven
applic
octagam
manufactur
octapharma
pharmazeutika
produktionsg
mbh
vienna
austria
fullscal
manufactur
sd
process
condit
includ
treatment
ww
tri
nbutyl
phosphat
tnbp
ww
octoxynol
trade
name
triton
g
c
ph
g
minimum
h
complianc
cpmp
robust
viru
inactiv
method
demonstr
experiment
therefor
inactiv
sarscov
sd
treatment
investig
laboratori
scale
lower
concentr
solvent
deterg
standard
sd
concentr
shorten
process
time
min
sarscov
isol
obtain
sputum
patient
hospitalis
diagnosi
probabl
sar
isol
unit
frankfurt
univers
hospit
germani
viru
stock
store
c
mainten
medium
consist
minimum
essenti
medium
mem
without
foetal
calf
serum
fc
supplement
iuml
penicillin
mgml
streptomycin
viru
propag
titrat
confluent
vero
cell
titr
determin
tissu
cultur
infect
dose
tcid
ml
microtitr
plate
replic
per
dilut
ml
inoculum
per
well
initi
titr
undilut
viru
stock
tcid
ml
g
log
tcid
ml
hereaft
refer
viru
stock
control
min
tcid
ml
g
log
tcid
ml
viru
stock
control
min
accord
recommend
work
involv
infecti
sarscov
perform
biosafeti
level
bsl
condit
facil
valid
experi
perform
accord
current
cpmp
guidelin
recommend
paulehrlichinstitut
germani
aim
studi
evalu
total
capac
sd
process
inactiv
sarscov
defin
minim
incub
time
inactiv
virus
detect
limit
exact
incub
time
sd
min
fig
furthermor
purpos
valid
studi
investig
impact
significantli
lower
concentr
tnbp
octoxynol
standard
sd
concentr
ie
ww
ww
octoxynol
viru
inactiv
sd
treatment
perform
g
c
ph
g
mention
incub
period
two
independ
test
downscal
version
manufactur
process
examin
establish
equival
downscal
manufacturingscal
intermedi
demonstr
eg
measur
protein
concentr
purif
igg
cryopoor
plasma
cohneoncley
method
appli
process
involv
sequenti
purif
protein
fraction
ad
variou
concentr
ethanol
concurr
adjust
ph
ionic
strength
temperatur
precipit
separ
fraction
c
iii
fraction
ii
consid
viral
safeti
relev
step
nonlipid
envelop
virus
start
materi
studi
process
intermedi
resuspend
fraction
ii
obtain
manufactur
scale
spike
viru
aliquot
start
materi
without
sd
individu
spike
also
viru
titrat
confirm
amount
viru
ad
spike
intermedi
without
sd
titrat
begin
process
virusspik
intermedi
control
min
end
process
virusspik
intermedi
control
min
separ
spike
requir
presenc
sd
reagent
initi
titr
virusspik
process
intermedi
would
repres
quantiti
viru
actual
inocul
infect
determin
endpoint
titrat
vero
cell
sd
treatment
termin
laboratori
studi
dilut
cell
cultur
medium
order
prove
inactiv
sd
termin
dilut
procedur
aliquot
ml
sd
contain
intermedi
predilut
cell
cultur
medium
solut
spike
viru
result
final
dilut
factor
respect
sd
termin
control
specif
nonspik
process
intermedi
obtain
control
procedur
test
potenti
cytotox
see
vero
cell
potenti
interfer
detect
low
viru
titr
control
serial
dilut
eight
cultur
inoculum
size
ml
dilut
establish
sampl
taken
min
sd
treatment
ml
dilut
correspond
ml
undilut
sampl
use
inoculum
min
inoculum
volum
increas
ml
correspond
ml
undilut
sampl
cell
cultur
maintain
co
incub
c
vero
cultur
examin
microscop
evalu
virusinduc
cytotox
cell
chang
viru
titr
calcul
accord
method
spearman
viru
titr
sampl
viru
replic
observ
determin
use
poisson
distribut
upper
confid
limit
convers
tcid
ml
concentr
viru
particl
divid
ln
therefor
viru
replic
limit
detect
theoret
though
low
content
virus
accept
log
tcid
ml
min
log
tcid
ml
min
process
time
viru
reduct
factor
quantit
determin
capac
process
step
inactiv
virus
calcul
ratio
viru
titr
detect
spike
octagam
intermedi
without
sd
viru
titr
potenti
present
sd
step
studi
appropri
inprocess
sampl
collect
octagam
fullscal
product
preadjust
ph
process
intermedi
supplement
sd
final
spike
sarscov
ratio
start
materi
ww
tnbp
ww
octoxynol
incub
g
c
min
determin
kinet
viru
inactiv
test
sampl
taken
predefin
interv
process
min
sd
treatment
termin
dilut
cell
cultur
medium
dilut
test
sampl
screen
suscept
cell
vero
sarscov
infect
bulk
analysi
sarscov
titr
detect
start
materi
prior
sd
treatment
g
log
tcid
ml
result
fig
tabl
demonstr
sarscov
complet
inactiv
limit
detect
within
min
sd
treatment
depend
sampl
volum
test
detect
limit
vari
log
tcid
ml
log
tcid
ml
independ
perform
test
similar
result
obtain
take
consider
variou
handl
procedur
laboratori
experi
eg
spike
viru
care
mix
virusspik
intermedi
steril
sampl
aliquot
dilut
cell
cultur
medium
termin
inactiv
process
less
min
requir
result
log
reduct
factor
g
log
tcid
ml
viru
stock
control
virusspik
intermedi
control
show
expect
valu
demonstr
valid
studi
tabl
mean
differ
viru
titr
begin
end
incub
period
log
tcid
ml
furthermor
termin
control
confirm
dilut
suffici
termin
inactiv
sarscov
sd
titr
differ
log
tcid
ml
cytotox
interfer
prestudi
dilut
found
noncytotox
interfer
sarscovvero
cell
system
titr
differ
log
tcid
ml
sar
outbreak
seem
halt
present
time
indic
stringent
control
measur
taken
prevent
persontoperson
transmiss
effect
nevertheless
remain
import
assess
possibl
risk
mode
spread
exampl
via
blood
transfus
applic
therapeut
plasma
product
immunoglobulin
gener
level
durat
viraemia
viral
load
plasma
pool
critic
paramet
risk
assess
emerg
virus
risk
sarscov
transmiss
via
blood
therapeut
plasma
product
seem
remot
particularli
sarscov
viraemia
seem
reach
longlast
high
titr
order
reduc
potenti
risk
sarscov
transmiss
transfus
cellular
blood
compon
screen
blood
donor
nucleic
acid
techniqu
nat
eg
pcr
might
use
furthermor
valuabl
obtain
inform
antisarscov
efficaci
viru
inactiv
step
like
sd
procedur
wide
use
mani
compani
worldwid
manufactur
therapeut
plasmaderiv
product
includ
immunoglobulin
accept
pharmaceut
product
reli
therapeut
benefit
alon
larg
extent
document
viral
safeti
sd
method
irrevers
disrupt
lipid
coat
envelop
virus
associ
bind
site
mild
process
condit
efficaci
sd
method
extens
valid
human
model
virus
weil
anim
studi
standard
robust
condit
productspecif
manufactur
process
due
nonselect
mode
action
sd
method
capabl
inactiv
virus
concern
eg
hiv
hbv
hcv
also
virus
test
routin
screen
blood
collect
centr
eg
human
tlymphotrop
viru
htlv
c
hgv
cmv
safeti
margin
plasmaderiv
medicin
product
valid
utilis
downscal
model
respect
manufactur
process
order
investig
inactiv
capac
broad
rang
physicochem
divers
model
virus
case
sarscov
sever
fact
argu
relev
term
plasma
product
safeti
firstli
alreadi
mention
report
sarscov
titr
plasma
low
secondli
extens
number
valid
studi
use
envelop
virus
indic
envelop
viru
sarscov
would
becom
properli
inactiv
well
hand
could
shown
sarscov
differ
behaviour
toward
physicochem
noxa
comparison
known
human
coronavirus
easili
destroy
common
disinfect
thu
prudent
perform
valid
studi
order
confirm
safeti
hypothesi
investig
sd
treatment
octagam
process
intermedi
result
rapid
inactiv
detect
limit
sarscov
compar
routin
manufactur
octagam
condit
sd
treatment
perform
challeng
significantli
inactiv
time
reduc
wherea
concentr
sd
reagent
decreas
product
condit
despit
worsen
process
condit
improv
level
detect
infecti
sarscov
could
found
min
sd
treatment
demonstr
robust
viru
inactiv
technolog
taken
account
start
viru
titr
reduct
factor
g
log
tcid
ml
current
investig
confirm
predict
behaviour
sarscov
treat
sd
describ
condit
corrobor
earlier
find
surpris
sd
method
confirm
effect
technolog
use
inactiv
envelop
virus
conclus
result
obtain
investig
demonstr
process
condit
specifi
sd
treatment
octagam
suffici
inactiv
envelop
virus
sarscov
limit
detect
safeti
margin
high
detect
limit
alreadi
reach
within
min
sd
exposur
even
significantli
reduc
concentr
tnbp
octoxynol
furthermor
convinc
inactiv
capac
kinet
extrem
process
condit
efficaci
standard
sd
treatment
use
octagam
inactiv
sarscov
must
even
higher
one
demonstr
studi
even
viru
load
higher
one
simul
studi
